> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-63/
- Published: 2022-02-21T12:00:00.000Z
- Updated: 2026-09-14T17:33:28.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139592

**Palatin Technologies** has entered into a collaboration and license agreement with Shanghai **Fosun Pharmaceutical Industrial Development Co.** to develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications. Bremelanotide is an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Under the agreement, Palatin will receive an upfront payment of $5 million and $7.5 million based on certain regulatory milestones.

**Natus Medical h**as agreed to acquire certain neurosurgery business assets from **Integra LifeSciences** for $47.5 million. As part of the transaction, Natus will acquire the global Camino ICP monitoring product line, including its San Diego manufacturing facility, from Integra. The transaction also includes the U.S. rights relating to Integra’s fixed pressure shunts, as well as U.S. rights to Codman’s Duraform dural graft implant, standard EVD catheters and CSF collection systems.

**Merck** has agreed to acquire **Rigontec**, a firm focused on accessing the retinoic acid-inducible gene I (RIG-I) pathway as an approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Rigontec’s lead candidate, RGT100, is currently in Phase 1 development evaluating treatment in patients with various tumors. Under the terms of the agreement, Merck will pay $150 million upfront and will provide another $453 million in milestone payments.